Current Research Studies

A Phase 2, Randomized, Open-Label Study Of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic-Graft-Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

Axa vs BAT for Ped cGVHD

  • Condition(s): Other Hematopoietic
  • Phase: II
  • Clinicaltrials.gov ID: NCT07124078

What is the goal of the study?

To assess the efficacy of axatilimab monotherapy versus BAT in cGVHD.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: